OncoTherapy Science, Inc. (TYO:4564)
21.00
0.00 (0.00%)
Aug 27, 2026, 1:50 PM JST
OncoTherapy Science Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 2,326 | 2,089 | 833 | 527 | 1,117 | 1,836 |
Cash & Short-Term Investments | 2,326 | 2,089 | 833 | 527 | 1,117 | 1,836 |
Cash Growth | 89.41% | 150.78% | 58.06% | -52.82% | -39.16% | -36.67% |
Accounts Receivable | 81 | 103 | 98 | 35 | 123 | 399 |
Other Receivables | - | - | - | 153 | - | - |
Receivables | 81 | 103 | 98 | 188 | 123 | 399 |
Inventory | 94 | 62 | 78 | 73 | 99 | 231 |
Other Current Assets | 62 | 55 | 96 | 29 | 83 | 134 |
Total Current Assets | 2,563 | 2,309 | 1,105 | 817 | 1,422 | 2,600 |
Long-Term Investments | 49 | 49 | 49 | 49 | 89 | 84 |
Other Long-Term Assets | - | 1 | 1 | 1 | - | 1 |
Total Assets | 2,612 | 2,359 | 1,155 | 867 | 1,511 | 2,685 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Current Income Taxes Payable | 200 | 142 | 163 | 141 | 318 | 558 |
Other Current Liabilities | 17 | 27 | 164 | 218 | 291 | 46 |
Total Current Liabilities | 217 | 169 | 327 | 359 | 609 | 604 |
Other Long-Term Liabilities | 47 | 49 | 100 | 155 | 48 | 102 |
Total Liabilities | 264 | 218 | 427 | 514 | 657 | 706 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 298 | 50 | 50 | 50 | 789 | 789 |
Additional Paid-In Capital | 30,087 | 29,839 | 27,516 | 26,322 | 24,793 | 24,793 |
Retained Earnings | -28,107 | -27,818 | -26,908 | -26,092 | -24,804 | -23,686 |
Comprehensive Income & Other | 70 | 70 | 70 | 73 | 76 | 83 |
Total Common Equity | 2,348 | 2,141 | 728 | 353 | 854 | 1,979 |
Shareholders' Equity | 2,348 | 2,141 | 728 | 353 | 854 | 1,979 |
Total Liabilities & Equity | 2,612 | 2,359 | 1,155 | 867 | 1,511 | 2,685 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Cash (Debt) | 2,326 | 2,089 | 833 | 527 | 1,117 | 1,836 |
Net Cash Growth | 89.41% | 150.78% | 58.06% | -52.82% | -39.16% | -36.67% |
Net Cash Per Share | 6.49 | 6.36 | 3.19 | 2.48 | 5.80 | 9.79 |
Filing Date Shares Outstanding | 398.82 | 398.64 | 277.64 | 239.34 | 206.64 | 192.64 |
Total Common Shares Outstanding | 398.82 | 383.64 | 271.64 | 217.64 | 192.64 | 192.64 |
Working Capital | 2,346 | 2,140 | 778 | 458 | 813 | 1,996 |
Book Value Per Share | 5.89 | 5.58 | 2.68 | 1.62 | 4.43 | 10.27 |
Tangible Book Value | 2,348 | 2,141 | 728 | 353 | 854 | 1,979 |
Tangible Book Value Per Share | 5.89 | 5.58 | 2.68 | 1.62 | 4.43 | 10.27 |